AI Tool Predicts Colon Cancer Survivorship and Response to Treatment | News Direct

AI Tool Predicts Colon Cancer Survivorship and Response to Treatment

News release by MarketJar

facebook icon linkedin icon twitter icon pinterest icon email icon Vancouver, BC | May 03, 2023 09:00 AM Eastern Daylight Time


Source: Freepik
Source: Freepik

Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options.

The new technique uses microscopic images of tumor samples to reliably predict colorectal tumor aggressiveness. It predicts survival with and without disease recurrence and the optimum treatment.

The new approach may help clinicians recommend more intense follow-ups, aggressive treatments, or clinical trials of newer drugs for individuals with poor prognosis. In areas with limited access to advanced pathology and tumor genetic sequencing, the strategy may be useful.

This new AI tool goes beyond mimicking or optimizing human expertise and can see visual patterns on microscope images that the naked eye cannot.

The algorithm was trained with patients' ages, sexes, cancer stages, and results using records from almost 2,000 colorectal cancer patients. The tumor's genomic, epigenetic, protein, and metabolic profiles were inputted.

The model pathologist was then presented tumor samples and instructed to look for visual markers of tumor types, genetic mutations, epigenetic alterations, disease progression, and patient survival.

The researchers showed the model novel pictures of tumor samples from multiple patients to test its "real-world" performance. To evaluate its efficacy, they matched its results to real patients and other clinical data.

After diagnosis, survival time and cancer-free years were accurately predicted.

The technology also projected how a patient's tumor would respond to certain medications based on genetic variations that made the cancer more or less likely to form or spread. The technique outperformed pathologists and cutting-edge AI algorithms.

The researchers believe this approach could assist guide treatment decisions in cases when resources are short or genetic sequencing of tumor tissue is not possible.

It could help clinicians and patients navigate colorectal cancer, which kills 1 million people globally each year.

When it comes to combating colon cancer, early detection is key. It’s also important that cancer detection is simple, accessible, and affordable.

Up until recently, a colonoscopy was the most accurate way to detect colon cancer. However, over one-third of eligible individuals refuse to undergo a colonoscopy, which is why non-invasive alternatives are needed.

Mainz Biomed (NASDAQ:MYNZ) is the company behind ColoAlert, a highly accurate and easy-to-use at-home screening test for colorectal cancer (CRC). This product is the first DNA-based screening test for colorectal cancer and is already approved in the European Union.

Revolutionary At-Home Cancer Screening Test Moves Toward FDA Approval

Mainz Biomed's flagship product ColoAlert, which is based on PCR technology, detects more cases of colorectal cancer than other stool tests and enables for early diagnosis.

The product is already commercially available in some EU nations through a network of top independent laboratories, corporate health programs, and direct sales and the company is working towards US approval.

The company has already successfully completed its pre-submission process, and IRB approval for its pivotal FDA study, ReconAAsense. That means that FDA approval could potentially be in the future and if that happens, it could send this company into a new dimension.

ColoAlert will be tested in a pivotal FDA-registration trial 'ReconAAsense' to acquire commercial approval in the United States. Once licensed in the US, Mainz Biomed’s goal is to build scalable distribution across the country through a collaborative partner program with regional and national laboratory service providers.

Mainz Biomed has joined Eurofins GeLaMed to its network of lab partners delivering PCR test kit processing of ColoAlert. Eurofins GeLaMed is part of Eurofins Scientific, a multinational laboratory business with over 61,000 people in 61 countries and 450 million tests per year. It has four facilities in Germany.

Eurofins GeLaMed offers advanced diagnostics in human genetics, medical microbiology, laboratory medicine, and molecular diagnostics in eleven medical departments. GeLaMed's over 500 staff process more than 15,000 orders each day and offer more than 2,000 analytical methods from their laboratory medicine and microbiological portfolios under medical professionals.

Eurofins Business Line Director Clinical Diagnostics DACH Marcus Cholewa said he was excited about Mainz Biomed and Eurofins GeLaMed's collaboration because Eurofins always provides excellent customer service, quality, advanced analytical solutions, and the most comprehensive testing methods. He also said that Eurofins has a history of providing innovative and high-value diagnostic testing solutions, and that by working, they might help identify colorectal cancer (CRC) and give patients individualized information to manage their health.

Under the agreement, Eurofins GeLaMed will offer ColoAlert at its testing sites and Mainz Biomed will help with physician and patient education programs for March Colorectal Cancer Awareness Month, emphasizing the importance of early screening for CRC detection and prevention.

Please visit this link for additional information on Mainz Biomed (NASDAQ:MYNZ) and its projects.




1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.


2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) seventy three thousand three hundred forty USD for 17 days (13 business days).


3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.


4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on


5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.


6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition.


Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.


7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities.


Contact Details


James Young


+1 800-340-9767


Company Website